Verdiva Bio Presents Preclinical Data on Investigational Obesity Drug Candidates at the American Diabetes Association 86th Scientific Sessions
Verdiva Bio Limited (“Verdiva Bio” or “the Company”), a clinical-stage biotechnology company advancing a scalable, once-weekly oral obesity product pipeline, today announced new preclinical data for VRB-103, a once-weekly oral amylin receptor-selective amylin analog, and VRB-104, a unimolecular amylin and GLP-1 receptor dual agonist. These data are being presented in poster sessions at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana.
Verdiva Bio to Present Preclinical Data on Investigational Obesity Drug Candidates at the American Diabetes Association 86th Scientific Sessions
Verdiva Bio Limited (“Verdiva Bio” or “the Company”), a clinical-stage biotechnology company advancing a scalable, once-weekly oral obesity product pipeline, today announced that two abstracts have been selected for poster presentations at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana. The presentations include new preclinical data for VRB-103, a once-weekly oral amylin receptor-selective amylin analog, and VRB-104, a unimolecular GLP-1 plus amylin co-agonist.
Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions
Verdiva Bio Limited (“Verdiva” or “the Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic disorders, will present new data showcasing the once-weekly potential of Verdiva’s investigational oral GLP-1RA and amylin analog peptide candidates at the American Diabetes Association (ADA) 85th Scientific Sessions.
Verdiva Bio, a New Clinical-Stage Cardiometabolic Company, Launches with Over $410M in Series A Financing to Advance Next-Generation Therapies
Verdiva Bio Limited (“Verdiva” or “the Company”) today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. The Company is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. Verdiva launches with an oversubscribed Series A financing of $411M, co-led by Forbion and General Atlantic, with additional participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital (collectively, “the Investor Group”).
